Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway

References

• Serrano PE, Carter DN, Li C, et al. Adjuvant chemotherapy with or without biologics including antiangiogenics and monoclonal antibodies targeting EGFR and EpCAM in colorectal cancer: a systematic review and meta-analysis. J Surg Res. 2019;239:14–21. doi:10.1016/j.jss.2019.01.03030782542
   PubMed Web of Science ®Google Scholar
• Valle L, de Voer RM, Goldberg Y, et al. Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med. 2019. doi:10.1016/j.mam.2019.03.001
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Zhao CG, Li HM, Lin HJ, Yang SL, Lin JY, Liang G. Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci. 2016;37(1):47–61. doi:10.1016/j.tips.2015.10.00126576830
   PubMed Web of Science ®Google Scholar
• Caetano MS, Hassane M, Van HT, et al. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun. 2018;9(1):4589. doi:10.1038/s41467-018-07042-y30389925
   PubMed Web of Science ®Google Scholar
• Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–746. doi:10.1038/nrc381825342631
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer. Oncology (Williston Park, NY). 2017;31(5):381–389.
   PubMed Web of Science ®Google Scholar
• Yakubu UM, Morano KA. Roles of the nucleotide exchange factor and chaperone Hsp110 in cellular proteostasis and diseases of protein misfolding. Biol Chem. 2018;399(10):1215–1221. doi:10.1515/hsz-2018-020929908125
   PubMed Web of Science ®Google Scholar
• Wang XY, Subjeck JR. High molecular weight stress proteins: identification, cloning and utilisation in cancer immunotherapy. Int J Hyperthermia. 2013;29(5):364–375. doi:10.3109/02656736.2013.80360723829534
   PubMed Web of Science ®Google Scholar
• Berthenet K, Bokhari A, Lagrange A, et al. HSP110 promotes colorectal cancer growth through STAT3 activation. Oncogene. 2017;36(16):2328–2336. doi:10.1038/onc.2016.40327819670
   PubMed Web of Science ®Google Scholar
• Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e207. doi:10.1016/S1470-2045(19)30145-730942181
   PubMed Web of Science ®Google Scholar
• Lauria A, Abbate I, Gentile C, Angileri F, Martorana A, Almerico AM. Synthesis and biological activities of a new class of heat shock protein 90 inhibitors, designed by energy-based pharmacophore virtual screening. J Med Chem. 2013;56(8):3424–3428. doi:10.1021/jm400202323520985
   PubMed Web of Science ®Google Scholar
• Gomha SM, Abdulla MM, Abou-Seri SM. Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors. Eur J Med Chem. 2015;92:459–470. doi:10.1016/j.ejmech.2015.01.01925594740
   PubMed Web of Science ®Google Scholar
• Kalaria PN, Satasia SP, Avalani JR, Raval DK. Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast. Eur J Med Chem. 2014;83:655–664. doi:10.1016/j.ejmech.2014.06.07125010936
   PubMed Web of Science ®Google Scholar
• Dev S, Dhaneshwar SR, Mathew B. Virtual combinatorial library design, synthesis and in vitro anticancer assessment of −2-amino-3-cyanopyridine derivatives. Comb Chem High Throughput Screen. 2018;21(2):138–148. doi:10.2174/138620732166618022811392529493450
   PubMed Web of Science ®Google Scholar
• Xu L, Qiu S, Yang L, et al. Aminocyanopyridines as anti-lung cancer agents by inhibiting the STAT3 pathway. Mol Carcinog. 2019;58:1512–1525. doi:10.1002/mc.2303831069881
   PubMed Web of Science ®Google Scholar
• ME IJ, Sanz-Pamplona R, Hermitte F, de Miranda N. Colorectal cancer: a paradigmatic model for cancer immunology and immunotherapy. Mol Aspects Med. 2019. doi:10.1016/j.mam.2019.05.003
   Web of Science ®Google Scholar
• La Vecchia S, Sebastian C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin Cell Dev Biol. 2019. doi:10.1016/j.semcdb.2019.05.018
   PubMed Web of Science ®Google Scholar
• Gozzi GJ, Gonzalez D, Boudesco C, et al. Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy. Cell Death Differ. 2019. doi:10.1038/s41418-019-0343-4
   PubMed Web of Science ®Google Scholar
• Kesselring R, Glaesner J, Hiergeist A, et al. IRAK-M expression in tumor cells supports colorectal cancer progression through reduction of antimicrobial defense and stabilization of STAT3. Cancer Cell. 2016;29(5):684–696. doi:10.1016/j.ccell.2016.03.01427150039
   PubMed Web of Science ®Google Scholar
• Wei N, Li J, Fang C, et al. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. Oncogene. 2019;38(10):1676–1687. doi:10.1038/s41388-018-0547-y30348989
   PubMed Web of Science ®Google Scholar
• Yang L, Lin S, Kang Y, et al. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway. J Exp Clin Cancer Res. 2019;38(1):31. doi:10.1186/s13046-018-1015-930674340
   PubMed Web of Science ®Google Scholar
• Zheng H, Yang L, Kang Y, et al. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Mol Carcinog. 2019;58(4):565–576. doi:10.1002/mc.2295130520143
   PubMed Web of Science ®Google Scholar